When will Amivantamab be included in medical insurance?

Amivantamab (Amivantamab) is an emerging biologic drug designed to treat a specific type of non-small cell lung cancer (NSCLC). It represents an innovation in the field of immunotherapy and has a unique mechanism of action, making it highly anticipated in cancer treatment. The mechanism of action of evantumumab is one of its outstanding features. It is a bispecific antibody capable of binding two different molecular targets simultaneously. By binding to these two receptors, evantumumab can simultaneously interfere with the growth signals of tumor cells, thereby slowing or inhibiting the proliferation and spread of cancer cells. Evantuzumab is not currently available in the country and is therefore not covered by medical insurance, so patients cannot purchase it domestically.